Toxicities and functional consequences of systemic chemotherapy in elderly Korean patients with cancer: A prospective cohort study using Comprehensive Geriatric Assessment

Shin, Dong Yeop; Lee, Jeong-Ok; Kim, Yu Jung; Park, Myung‐Sook; Lee, Keun-Wook; Kim, Kwang Il; Bang, Soo Mee; Lee, Jong-Seok; Kim, Cheol-Ho; Kim, Jee Hyun

doi:10.1016/j.jgo.2012.06.002

Cited by 17 publications

(32 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the most important limitations in the existing literature regarding chemotherapy and fragility are the retrospective nature of these studies, small sample size, and lack of power to determine clinically relevant changes . Table summarizes the characteristics of some of the important frailty studies that have reported outcome data other than surgery …”

Section: Frailty and Chemotherapymentioning

confidence: 99%

“…Significant declines were seen after chemotherapy in ECOG‐PS, activities of daily living, Instrumental Activities of Daily Living, Mini‐Mental Status Examination scores, and short‐form Geriatric Depression Scale assessments. Baseline ECOG‐PS was an independent predictive factor of significant toxicity, and a mininutritional assessment was marginally associated with significant toxicity in univariate analysis . Biesma et al reported a phase 3 study in 181 chemotherapy‐naive patients with advanced non‐small cell lung cancer.…”

Section: Frailty and Chemotherapymentioning

confidence: 99%

See 1 more Smart Citation

Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology

Ethun

Bilen

Jani

et al. 2017

CA A Cancer J Clinicians

456

324

View full text Add to dashboard Cite

https://www.wileyhealthlearning.com/acs.aspx The concept of frailty has become increasingly recognized as one of the most important issues in health care and health outcomes and is of particular importance in patients with cancer who are receiving treatment with surgery, chemotherapy, and radiotherapy. Because both cancer itself, as well as the therapies offered, can be significant additional stressors that challenge a patient's physiologic reserve, the incidence of frailty in older patients with cancer is especially high—it is estimated that over one‐half of older patients with cancer have frailty or prefrailty. Defining frailty can be challenging, however. Put simply, frailty is a state of extreme vulnerability to stressors that leads to adverse health outcomes. In reality, frailty is a complex, multidimensional, and cyclical state of diminished physiologic reserve that results in decreased resiliency and adaptive capacity and increased vulnerability to stressors. In addition, over 70 different measures of frailty have been proposed. Still, it has been demonstrated that frail patients are at increased risk of postoperative complications, chemotherapy intolerance, disease progression, and death. Although international standardization of frailty cutoff points are needed, continued efforts by oncology physicians and surgeons to identify frailty and promote multidisciplinary decision making will help to develop more individualized management strategies and optimize care for patients with cancer. CA Cancer J Clin 2017;67:362–377. © 2017 American Cancer Society.

show abstract

Section: Frailty and Chemotherapymentioning

confidence: 99%

Section: Frailty and Chemotherapymentioning

confidence: 99%

Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology

Ethun

Bilen

Jani

et al. 2017

CA A Cancer J Clinicians

456

324

View full text Add to dashboard Cite

show abstract

“…GA has been shown to improve outcomes in older adults in the geriatric medicine setting, with regard to reduced hospital admissions, improved functional status and better survival (Ellis et al, 2011, Stuck et al, 1993). The evidence for the benefits of GA in oncology include prediction of treatment related toxicity (Hurria et al, 2011, Shin et al, 2012, Aparicio et al, 2013, Extermann et al, 2012), treatment adherence (Puts et al, 2014, Spyropoulou et al, 2014, Kim et al, 2014), quality of life (Pottel et al, 2014, Ward et al, 2014), ability to inform oncologist's treatment decisions (Kenis et al, 2013, Caillet et al, 2011, Horgan et al, 2012, Aliamus et al, 2011, Aparicio et al, 2011, Decoster et al, 2013) and overall survival (Hamaker et al, 2011, Girones et al, 2011, Kanesvaran et al, 2011, Soubeyran et al, 2012). However, much of the current knowledge base for the effectiveness of GA in oncology is based on smaller retrospective studies of heterogeneous cancer patients, and better prognostic models are needed (Wildiers et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Expert consensus panel guidelines on geriatric assessment in oncology

2015

View full text Add to dashboard Cite

Introduction Despite consensus guidelines on best practice in the care of older patients with cancer, geriatric assessment (GA) has yet to be optimally integrated into the field of oncology in most countries. There is a relative lack of consensus in the published literature as to the best approach to take, and there is a degree of uncertainty as to how integration of geriatric medicine principles might optimally predict patient outcomes. The aim of the current study was to obtain consensus on GA in oncology to inform the implementation of a geriatric oncology programme. Methods A four round Delphi process was employed. The Delphi method is a structured group facilitation process, using multiple iterations in order to gain consensus on a given topic Results Consensus was reached on the optimal assessment method and interventions required for the commonly employed domains of GA. Other aspects of GA, such as screening methods and age cutoff for assessment represented a higher degree of disagreement. Discussion The expert panel employed in this study clearly identified the criteria that should be included in a clinical geriatric oncology programme. In the absence of evidence-based guidelines, this may prove useful in the care of older cancer patients.

show abstract

“…Characteristics of included studies are presented in Table 1 . Eighteen studies were prospective cohort studies [24][25][26][27][28][29][30][31][32][33][34][35]38,41,43,[45][46][47][48][49]51,52], and nine were retrospective studies [36,37,39,40,42,44,50,51,53].…”

Section: Resultsmentioning

confidence: 99%

Patient- and tumor-related predictors of chemotherapy intolerance in older patients with cancer: A systematic review

Abbema

Akker

Janssen‐Heijnen

et al. 2019

Journal of Geriatric Oncology

View full text Add to dashboard Cite

show abstract

Toxicities and functional consequences of systemic chemotherapy in elderly Korean patients with cancer: A prospective cohort study using Comprehensive Geriatric Assessment

Cited by 17 publications

References 42 publications

Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology

Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology

Expert consensus panel guidelines on geriatric assessment in oncology

Patient- and tumor-related predictors of chemotherapy intolerance in older patients with cancer: A systematic review

Contact Info

Product

Resources

About